Key Takeaways
- Shares of Moderna surged approximately 13% to $67.50, marking the highest closing price since September 2024, driven by announcements at its investor day presentation.
- The biotech firm introduced mRNA-6007, its inaugural in vivo CAR-T therapy program, aimed at autoimmune conditions such as lupus, with clinical trials scheduled to start in 2027.
- A unanimous 9-0 vote from an FDA advisory committee supported approval of Moderna’s influenza vaccine for individuals aged 50 and above, with a final FDA ruling expected on August 5, 2026.
- Jefferies analyst Andrew Tsai increased his price target to $53 from $45, while Piper Sandler’s Edward Tenthoff boosted his to $77, reaffirming an Overweight stance.
- Overall Street sentiment remains neutral with a Hold consensus rating and an average price target of $45.42 — suggesting potential downside from current price levels.
Shares of Moderna (MRNA) experienced a substantial rally on Friday, climbing roughly 13% to reach $67.50, positioning the biotech stock for its strongest close since September of last year. The impressive gain made MRNA the standout performer within the S&P 500 during the trading session. Intraday, shares briefly spiked nearly 15%, approaching the $69 level.
The surge was triggered by Moderna’s investor day presentation, during which the company unveiled an extensive expansion of its drug development pipeline that reaches far beyond its COVID-19 vaccine foundation.
MRNA has now advanced approximately 42% over the past 30 days, indicating a notable shift in market sentiment toward the stock.
The marquee reveal was mRNA-6007, Moderna’s inaugural in vivo CAR-T therapy program. The company intends to initiate clinical development by 2027, with an initial focus on B-cell-driven autoimmune disorders, particularly systemic lupus erythematosus.
Unlike conventional ex vivo CAR-T treatments that require removing patient T-cells, engineering them in laboratory settings, and reinfusing them, in vivo CAR-T therapy reprograms T-cells directly within the patient’s body. This approach offers greater efficiency and reduced costs.
Moderna isn’t the only pharmaceutical company pursuing this cutting-edge technology. Earlier this year, Eli Lilly acquired Orna Therapeutics primarily to gain access to its in vivo CAR-T platform. Notably, Lilly shares also rose 6% on Friday, boosted by favorable feedback from European regulators regarding its oral cancer treatment.
Strategic Roadmap Divided Into Three Phases
Moderna presented its strategic vision organized into three separate “horizons.” The initial phase emphasizes advanced, near-commercial assets, including current marketed products and late-stage pipeline candidates.
Jefferies analyst Andrew Tsai projects the company could launch more than seven new products spanning respiratory, oncology, and rare disease categories within the next two years. This would represent a significant expansion from its current portfolio of three approved vaccines.
Tsai highlighted Phase III melanoma trial results, anticipated in the latter half of 2026, as a critical upcoming milestone, describing it as “a major event” for shareholder value. He maintains a Hold rating while elevating his price target to $53 from the previous $45.
Another program drawing considerable attention is mRNA-4194, Moderna’s pioneering cancer prevention therapy designed for Lynch syndrome patients. Additionally, the company is progressing with mRNA-1195, its multiple sclerosis candidate, which should generate preliminary data later in 2026.
Influenza Vaccine Provides Additional Momentum
Beyond oncology and autoimmune therapeutics, Moderna received encouraging news regarding its flu vaccine candidate mRNA-1010 when an FDA advisory committee delivered a unanimous 9-0 vote recommending approval for adults 50 years and older.
The FDA’s final determination is scheduled for August 5, 2026. Approval would provide the company with another revenue-generating product independent of its COVID franchise.
Piper Sandler analyst Edward Tenthoff elevated his price target to $77 from $69 and maintained an Overweight rating, citing the substantial progress showcased during the investor day event.
However, despite positive reactions from select analysts, the broader Wall Street consensus remains at Hold, comprising two Buy ratings, 19 Hold ratings, and three Sell ratings across the past three months. The consensus price target of $45.42 suggests more than 31% potential downside from current trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
